open access

Vol 70, No 3 (2019)
Original Paper
Published online: 2019-03-07
Submitted: 2018-10-20
Accepted: 2019-01-24
Get Citation

The influence of the reclassification of NIFTP as an uncertain tumour on risk of malignancy for the diagnostic categories according to the Bethesda system for reporting thyroid cytopathology

Janusz Kopczyński, Agnieszka Suligowska, Kornelia Niemyska, Iwona Palyga, Agnieszka Walczyk, Danuta Gąsior-Perczak, Artur Kowalik, Kinga Hińcza, Ryszard Mężyk, Stanisław Góźdź, Aldona Kowalska
DOI: 10.5603/EP.a2019.0008
·
Pubmed: 30845342
·
Endokrynologia Polska 2019;70(3):232-236.

open access

Vol 70, No 3 (2019)
Original Paper
Published online: 2019-03-07
Submitted: 2018-10-20
Accepted: 2019-01-24

Abstract

Introduction: The noninvasive encapsulated, follicular variant of papillary thyroid carcinoma was reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The exclusion of NIFTP from the group of malignant tumours decreases the risk of malignancy (RoM) as defined by the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The aim of the present study was to evaluate the RoM for each category in TBSRTC with and without exclusion of NIFTP from the tally of malignancies.

Material and methods: The present study included 998 thyroid nodules cases. All patients underwent diagnostic tests, including fine-needle aspiration cytology, and received surgical treatment. Slides for all resection specimens with a diagnosis of cancer were reviewed to identify NIFTP. The RoM for each of the categories in TBSRTC with and without exclusion of NIFTP from the malignant tumours was evaluated.

Results: The RoM decreased with the exclusion of NIFTP from malignant categorisation with the following values for the different TBSRTC categories: non-diagnostic (ND): 0%; benign: 0%; atypia/follicular lesion of undetermined significance (AUS/FLUS): 1.6%; follicular neoplasm/suspicious for follicular neoplasm (FN/SFN): 0.7%; suspicious for malignancy (SUS): 6.9%; and malignant: 2.5%. The difference of 2.5% in the malignant category was statistically significant (p = 0.0253).

Conclusions: The RoM for specific TBSRTC categories needs to be defined for each treatment centre because it is important for the selection of the appropriate surgical treatment for thyroid tumours.

Abstract

Introduction: The noninvasive encapsulated, follicular variant of papillary thyroid carcinoma was reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The exclusion of NIFTP from the group of malignant tumours decreases the risk of malignancy (RoM) as defined by the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). The aim of the present study was to evaluate the RoM for each category in TBSRTC with and without exclusion of NIFTP from the tally of malignancies.

Material and methods: The present study included 998 thyroid nodules cases. All patients underwent diagnostic tests, including fine-needle aspiration cytology, and received surgical treatment. Slides for all resection specimens with a diagnosis of cancer were reviewed to identify NIFTP. The RoM for each of the categories in TBSRTC with and without exclusion of NIFTP from the malignant tumours was evaluated.

Results: The RoM decreased with the exclusion of NIFTP from malignant categorisation with the following values for the different TBSRTC categories: non-diagnostic (ND): 0%; benign: 0%; atypia/follicular lesion of undetermined significance (AUS/FLUS): 1.6%; follicular neoplasm/suspicious for follicular neoplasm (FN/SFN): 0.7%; suspicious for malignancy (SUS): 6.9%; and malignant: 2.5%. The difference of 2.5% in the malignant category was statistically significant (p = 0.0253).

Conclusions: The RoM for specific TBSRTC categories needs to be defined for each treatment centre because it is important for the selection of the appropriate surgical treatment for thyroid tumours.

Get Citation

Keywords

noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); risk of malignancy (RoM); thyroid cancer; Bethesda system

About this article
Title

The influence of the reclassification of NIFTP as an uncertain tumour on risk of malignancy for the diagnostic categories according to the Bethesda system for reporting thyroid cytopathology

Journal

Endokrynologia Polska

Issue

Vol 70, No 3 (2019)

Pages

232-236

Published online

2019-03-07

DOI

10.5603/EP.a2019.0008

Pubmed

30845342

Bibliographic record

Endokrynologia Polska 2019;70(3):232-236.

Keywords

noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)
risk of malignancy (RoM)
thyroid cancer
Bethesda system

Authors

Janusz Kopczyński
Agnieszka Suligowska
Kornelia Niemyska
Iwona Palyga
Agnieszka Walczyk
Danuta Gąsior-Perczak
Artur Kowalik
Kinga Hińcza
Ryszard Mężyk
Stanisław Góźdź
Aldona Kowalska

References (28)
  1. Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017; 317(13): 1338–1348.
  2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295(18): 2164–2167.
  3. La Vecchia C, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015; 136(9): 2187–2195.
  4. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic" — screening and overdiagnosis. N Engl J Med. 2014; 371(19): 1765–1767.
  5. Jung CK, Little MP, Lubin JH. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014; 99(1): 276–284.
  6. Lin HW, Bhattacharyya N. Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope. 2010; 120(4): 712–716.
  7. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102(9): 605–613.
  8. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016; 2(8): 1023–1029.
  9. Haugen BR, Sawka AM, Alexander EK, et al. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017; 27(4): 481–483.
  10. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27(11): 1341–1346.
  11. Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Thyroid. 2009; 19(11): 1159–1165.
  12. Fisher SB, Perrier ND. The incidental thyroid nodule. CA Cancer J Clin. 2018; 68(2): 97–105.
  13. Zhou H, Baloch ZW, Nayar R, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Implications for the risk of malignancy (ROM) in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). Cancer Cytopathol. 2018; 126(1): 20–26.
  14. Faquin WC, Wong LQ, Afrogheh AH, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol. 2016; 124(3): 181–187.
  15. Strickland KC, Howitt BE, Marqusee E, et al. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015; 25(9): 987–992.
  16. Lau RP, Paulsen JD, Brandler TC, et al. Impact of the Reclassification of "Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma" to "Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features" on the Bethesda System for Reporting Thyroid Cytopathology: A Large Academic Institution's Experience. Am J Clin Pathol. 2017; 149(1): 50–54.
  17. Canberk S, Gunes P, Onenerk M, et al. New concept of the encapsulated follicular variant of papillary thyroid carcinoma and its impact on the Bethesda System for reporting thyroid cytopathology: a single-institute experience. Acta Cytol. 2016; 60(3): 198–204.
  18. Layfield LJ, Baloch ZW, Esebua M, et al. Impact of the reclassification of the non-invasive follicular variant of papillary carcinoma as benign on the malignancy risk of the Bethesda System for reporting thyroid cytopathology: a meta-analysis study. Acta Cytol. 2017; 61(3): 187–193.
  19. Li WSB, Pang J, Lew M, et al. Implementing NIFTP may potentially impact the risk of malignancy for thyroid nodules categorized as FLUS and SFN. Mod Pathol. 2017; 30: 104A.
  20. Range DEHG, Jiang X. The impact of reclassification of encapsulated follicular variant of papillary thyroid carcinoma on the risk of malignancy in the Bethesda System for Reporting of Thyroid Cytopathology. Mod Pathol. 2017; 30: 147A.
  21. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. Endokrynol Pol. 2018; 69(1): 34–74.
  22. de Benoist B, McLean E, Andersson M, et al. Iodine deficiency in 2007: global progress since 2003. Food Nutr Bull. 2008; 29(3): 195–202.
  23. Gietka-Czernel M. Iodine prophylaxis. Post Nauk Med. 2015; 12: 839–845.
  24. Kakudo K, El-Naggar AK, Hodak SP, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in thyroid tumor classification. Pathol Int. 2018; 68(6): 327–333.
  25. Marti JL, Jain KS, Morris LGT. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid. 2015; 25(6): 681–687.
  26. Aschebrook-Kilfoy B, Schechter RB, Shih YCT, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013; 22(7): 1252–1259.
  27. Kandil E, Noureldine SI, Abbas A, et al. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery. 2013; 154(6): 1346–52; discussion 1352.
  28. Kiernan CM, Weiss VL, Mehrad M, et al. New terminology — noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP) and its effect on the rate of malignancy at a single institution. Surgery. 2018; 163(1): 55–59.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl